872624-52-7

Basic information

• Product Name: methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate
• Synonyms: methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate;Benzoic acid, 2-aMino-5-iodo-4-(trifluoroMethyl)-, Methyl ester;2-AMino-5-iodo-4-trifluoroMethyl-benzoic acid Methyl ester;methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate 97%;Methyl 2-amino-4-trifluoromethyl-5-iodobenzoate
• CAS NO: 872624-52-7
• Molecular Formula: C₉H₇F₃INO₂
• Molecular Weight: 345.06
• Mol File: 872624-52-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 347.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.863±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.72±0.10(Predicted)
• CAS DataBase Reference: methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate(872624-52-7)
• EPA Substance Registry System: methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate(872624-52-7)

Safety Data

• Hazardous Substances Data: 872624-52-7(Hazardous Substances Data)

Usage

General Description

Methyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate is a synthetic compound that contains a methyl ester, an amino group, and an iodine atom attached to a benzene ring with a trifluoromethyl group. It is commonly used as a building block in organic synthesis and medicinal chemistry, and its unique structure makes it a valuable tool for creating novel drug candidates and research compounds. The combination of functional groups in this chemical allows for a wide range of potential reactions and modifications, making it a versatile and important molecule in the development of pharmaceuticals and other organic compounds.

Upstream product

• 61500-87-6 methyl 2-Amino-4-(trifluoromethyl)benzoate 
• 320-94-5 2-nitro-4-trifluoromethylbenzoic acid 

Downstream Products

• 872624-91-4 2-amino-4-trifluoromethyl-5-vinyl-benzoic acid methyl ester 
• 872624-53-8 methyl 2-amino-5-methyl-4-trifluoromethylbenzoate 
• 912573-57-0 2-acetylamino-5-iodo-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-18-6 2-amino-5-ethynyl-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-17-5 2-amino-4-trifluoromethyl-5-trimethylsilanylethynyl-benzoic acid methyl ester 
• 912574-10-8 2-amino-5-(3-methoxy-prop-1-ynyl)-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-26-6 2-amino-5-[5-methyl-2-(2-trimethylsilanylmethoxy-ethyl)-2H-pyrazol-3-yl]-4-trifluoromethyl-benzoic acid methyl ester 
• 912574-87-9 2-amino-5-(2-benzyloxy-2H-pyrazol-3-yl)-4-trifluoromethyl-benzoic acid methyl ester 
• 1350742-37-8 2-amino-5-(2-ethyl-2H-pyrazol-3-yl)-4-trifluoromethyl-benzoic acid methyl ester 
• 1427400-33-6 2-amino-5-iodo-4-(trifluoromethyl)benzoic acid 
• 61500-87-6 methyl 2-Amino-4-(trifluoromethyl)benzoate 

Relevant articles and documents

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be asso

Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist

A series of potent quinazolinedione sulfonamide antagonists of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor were designed and synthesized. The structure–activity relationships (SAR) and in vivo activity of the series were investigated. In particular, compound 1 S (selurampanel; N-[7-isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methanesulfonamide) has shown excellent oral potency against maximal electroshock seizure (MES)-induced generalized tonic–clonic seizures in rodents as well as significant activity in patients suffering from various forms of epilepsy. The X-ray crystal structure of selurampanel bound to the AMPA receptor hGluA was also obtained.

1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS

The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schizophrenia, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) and combinations comprising compounds of formula (I) are disclosed.